The U.S. Food and Drug Administration is advising consumers to stop use immediately of a prescription drug marketed by a Scottsdale-based company.

Limbrel is a product in capsule form currently being manufactured as a medical food to manage the metabolic processes associated with osteoarthritis.

The FDA says 194 adverse cases have been reported involving the use of Limbrel that include serious liver injury and lung damage. 

Liver injury symptoms include jaundice, nausea, fatigue and gastrointestinal discomfort. Lung damage symptoms include fever, chills and shortness of breath.

The FDA says users should stop use of Limbrel immediately and contact a health provider.

According to the announcement, the FDA is continuing to investigate Scottsdale-based Primus Pharmaceuticals and the manufacturing process of Limbrel and is encouraging patients to check information through the MedWatch Safety Information and Adverse Event Reporting Program.